Braulangin - instructions for use, dose, side effects, contraindications

Excipients: lactose, potato starch, sodium hydrogen carbonate, basin, magnesium stearate, calcium stearate, polyvinylpyrrolidone low molecular weight.

Description:

Tablets are white or white with a yellowish shade of color, flat-cylindrical with a facet and a risk.

Pharmacotherapeutic group:Analgesic and antispasmodic

ATX: & nbsp

N.02.B.B.52 Metamizole sodium in combination with other drugs, excluding psycholeptics

Pharmacodynamics:

Braangin - a combined drug, has analgesic, antipyretic and antispasmodic effect.

Metamizole sodium is a derivative of pyrazolone. It has analgesic, antipyretic and weak anti-inflammatory action. Petophenone, like papaverine, causes relaxation of the smooth muscles of the internal organs due to direct myotropic action. Fenpiverinia bromide due to anticholinergic action has an additional relaxing effect on smooth muscle.

Indications:

Pain syndrome with spasms of smooth muscles of internal organs - renal and biliary colic, intestinal spasms, algodismenorea and other spastic conditions of internal organs.

Short-term symptomatic treatment for pain after surgical and diagnostic interventions, arthralgia, neuralgia, ischialgia, myalgia.

Contraindications:

Hypersensitivity to the components of the drug, expressed violations of the liver and kidneys.

Genetic absence of glucose-6-phosphate dehydrogenase.

Tachyarrhythmia, angle-closure glaucoma, prostatic hypertrophy with a tendency to urine retention, gastrointestinal obstruction and megalocone.

Diseases of the blood system (leukopenia, granulocytopenia, acute "intermittent" porphyria).

Severe arterial hypotension.

Pregnancy (especially the I trimester and the last 6 weeks before childbirth), lactation period.

Children's age (up to 5 years).

Carefully:

With caution and under the supervision of a doctor, the drug should be administered to patients with impaired liver or kidney function, with a tendency to arterial hypotension (systolic pressure below 100 mmHg). bronchospasm, as well as with increased individual sensitivity to non-steroidal anti-inflammatory drugs or non-narcotic analgesics.

Children and adolescents under 18 years of age should only take the drug for the intended use doctor.

Pregnancy and lactation:

Use in nursing mothers requires the cessation of breastfeeding.

Dosing and Administration:

Adults and children over 15 years of age apply! inside (better after eating) usually 1-2 tablets 2-3 times a day. The daily dose should not exceed 6 tablets. Duration of reception no more than 5 days.

Dosage for children 5-8 years - 1/2 tablet, 9-12 years - 3/4 pills. 13-15 years - one tablet 2-3 times a day. Duration of admission in children no more than 3 days.

Side effects:

In therapeutic doses, the drug is usually well tolerated. Allergic reactions are possible (skin rash, itching, hives, Quincke's edema, rarely anaphylactic shock, in very rare cases, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome).

Rarely (usually chronic administration, or high doses) - agranulocytosis, leukopenia, thrombocytopenia; disturbance of kidney function: oliguria. anuria, proteinuria, interstitial nephritis; bronchospasm, lowering of blood pressure, gastralgia, staining of urine in red.

Very rarely - anticholinergic effects (dry mouth, decreased sweating, paresis of accommodation, tachycardia, urine retention.).

All side effects should be reported to your doctor.

Overdose:Symptoms: vomiting, decreased blood pressure, drowsiness, confusion, nausea, vomiting, epigastric pain, liver function abnormalities and nochek, convulsions. The patient should stop taking the drug and consult a doctor}. Treatment: gastric lavage, Activated carbon, symptomatic therapy.

Interaction:

Simultaneous application of Bralangin with other non-narcotic analgesics can lead to mutual enhancement of toxic effects. Tricyclic antidepressants. contraceptive means for oral administration, allopurinol increase the toxicity of the drug. Barbiturates, phenylbutazone weaken the action of metamizole sodium.Simultaneous use with cyclosporine reduces the level of the latter in the blood. Sedatives and tranquilizers increase the analgesic effect of Braalangin.

If you need to use these and other medications at the same time, you should consult your doctor.

Special instructions:

During the treatment with the drug, you should not take alcohol.

In the process of treatment, it is necessary to control the content of leukocytes in peripheral blood. If suspected of agranulocytosis or in the presence of thrombocytopenia should stop taking the drug.

Effect on the ability to drive transp. cf. and fur:

During treatment, it is not recommended to drive vehicles and engage in potentially hazardous activities requiring fast physical and mental reaction.

Form release / dosage:

Pills.

Packaging:

10, 20 tablets in a can of orange glass or in a can or a glass-mass vial for medicines;
10, 20 tablets in a plastic container and a plastic vial.

10 tablets in a planar cell package. Each bank, container, vial, 1, 2 or 10 contour packs in a pack.

Storage conditions:

Store in a dry, dark place, out of the reach of children, at a temperature of no higher than 25 ° C.

Shelf life:

Shelf life 3 years. Do not use after the time specified on the package.

Terms of leave from pharmacies:Without recipe

Registration number:P N000704 / 02-2003

Date of registration:14.07.2008

Expiration Date:Unlimited

The owner of the registration certificate:BRYNTSALOV-A, CJSC BRYNTSALOV-A, CJSC Russia

Manufacturer: & nbsp

BRYNTSALOV-A, CJSC Russia

Information update date: & nbsp21.02.2017

Illustrated instructions

Instructions

Bralangin® (Bralangine®)